Comparative Pharmacology
Head-to-head clinical analysis: ORSYTHIA versus ORTHO EVRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORSYTHIA versus ORTHO EVRA.
ORSYTHIA vs ORTHO EVRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal aromatase inhibitor that selectively and reversibly inhibits aromatase, the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in tissues.
Combination hormonal contraceptive containing ethinyl estradiol and norelgestromin. Ethinyl estradiol suppresses gonadotropin (FSH and LH) release, preventing ovulation. Norelgestromin is a progestin that also inhibits ovulation and induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
400 mg orally twice daily
Transdermal: Apply one patch (releases 150 mcg norelgestromin and 20 mcg ethinyl estradiol per 24 hours) weekly for 3 weeks, followed by 1 patch-free week. Apply to clean, dry, intact skin on lower abdomen, buttock, upper arm, or upper torso (excluding breasts).
None Documented
None Documented
Terminal half-life ~12 hours (range 10-14 h); prolonged in renal impairment (up to 24-30 h).
Norelgestromin: ~28 hours (range 21-36) allowing weekly dosing; Ethinyl estradiol: ~17 hours (range 13-21)
Primarily renal (≥90% as unchanged drug); <5% biliary/fecal.
Renal: ~50% (as glucuronide conjugates of norelgestromin and ethinyl estradiol); Fecal: ~35% (as metabolites); Biliary: minor
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive